Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications

@article{Perucca2020CriticalAA,
  title={Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications},
  author={Emilio Perucca and Meir Bialer},
  journal={CNS Drugs},
  year={2020},
  pages={1-6}
}
This article provides a critical appraisal of the available evidence concerning clinical exposure to orally administered cannabidiol (CBD), with special reference to factors affecting gastrointestinal absorption, presystemic elimination, and susceptibility to metabolic drug interactions. Although detailed studies have not been published, the available data suggest that the absolute bioavailability of CBD after oral dosing under fasting conditions is approximately 6%, and increases fourfold when… 

Food effects on the formulation, dosing, and administration of cannabidiol (CBD) in humans: A systematic review of clinical studies

After the normalization of all the pharmacokinetic data sets by dose and patient weight, CBD exhibited a much greater bioavailability in fed patients, and the main excipient of oral CBD formulations (refined sesame seed oil) as a major contributor to the dose‐dependent variations in CBD pharmacokinetics, especially affecting the fasted state.

Current trends on cannabidiol delivery systems: where are we and where are we going?

Researchers concluded that the developed CBD-ADS can be used as an alternative to traditional formulations because they show comparable or superior effectiveness in treatment protocols.

A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery.

Compared to currently available drugs on the market, higher AUC values could be detected for the oromucosal cannabinoid spray AP701 despite administration of a lower dose, which may provide an easily applicable and titratable drug formulation with a high safety and tolerability profile.

Cannabidiol drug interaction considerations for prescribers and pharmacists.

An overview of evidence-based pharmacokinetic predictions and general guidance about the dose range at which clinically relevant cannabidiol drug interactions are likely are likely is provided.

The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations

Evidence for CBD undergoing hepatic first-pass liver metabolism and lymphatic absorption to a clinically important extent is discussed and the potential interplay between improved oral absorption, diversion of orally absorbed drug to the lymphatic system, and magnitude of presystemic elimination in the liver is discussed.

Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain

The objective of this review is to present the most recent results from pharmaceutical companies and research groups investigating methods to improve cannabinoid bioavailability and to clearly establish its therapeutic efficacy, dose ranges, safety and also improve the patient compliance.

Development and Pharmacokinetic Evaluation of a Self-Nanoemulsifying Drug Delivery System for the Oral Delivery of Cannabidiol.

  • Lie Yun KokPauric Bannigan C. Allen
  • Biology, Chemistry
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2021

Cannabidiol in Pharmacoresistant Epilepsy: Clinical Pharmacokinetic Data From an Expanded Access Program

These are the first data on CBD pharmacokinetics in children and adults with LGS or DS in a real-world setting and the most relevant finding was the higher CBD C/D in adults.

References

SHOWING 1-10 OF 50 REFERENCES

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans

The paucity in data and some discrepancy in the pharmacokinetics of cannabidiol are highlighted, despite its widespread use in humans, and robust data from a variety of formulations is required.

A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment

Renal impairment had no effect on the metabolism of CBD after a single oral 200 mg dose; CBD was generally well tolerated in subjects with varying degrees of renal function and no urinary pharmacokinetic parameters could be derived.

Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy

Current knowledge on the pharmacokinetics and metabolic fate of CBD in humans is summarized, studies on the biological activity of CBD metabolites either in vitro or in vivo are reviewed, and relevant drug–drug interactions are discussed.

Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines.

Co-administration of dietary lipids or pharmaceutical lipid excipients has the potential to substantially increase the exposure to orally administered cannabis and cannabis-based medicines.

Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration.

The disposition of deuterium-labelled cannabidiol, 2H2-CBD, was studied in five young men who were marihuana smokers and a four-fold difference in the availability of the compound was noted for the five subjects.

Pharmacokinetics and Pharmacodynamics of Cannabinoids

Properties of cannabis that might be of therapeutic use include analgesia, muscle relaxation, immunosuppression, sedation, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and induction of apoptosis in cancer cells.

Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects.

Omnisol gives a quick onset of pharmacodynamic effects in healthy volunteers, which implies a rapid initiation of therapeutic effects in patients and showed promising PK and PD characteristics.

A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment

Findings indicate that dose modification is necessary in patients with moderate and severe hepatic impairment, and a lower starting dose and slower titration are necessary based on benefit‐risk.

Plasma delta‐9‐tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking

After oral THC, the onset of clinical effects was much slower and lasted longer, but effects occurred at much lower plasma concentrations than after the other two methods of administration, suggesting that brain concentrations were increasing as plasma concentrations decreased.

Pharmacokinetics of urinary metabolites of cannabidiol in the dog

The pharmacokinetics of cannabidiol and six of its urinary metabolites was investigated in dogs, indicating that the elimination of these metabolites was formation rate limited.